---
title: "SelectQuote raises FY2025 revenue guidance to $1.5B-$1.575B amid strong Medicare Advantage performance"
date: "2025-02-11 23:06:33"
summary: "Earnings Call Insights: SelectQuote (NYSE:SLQT) Q2 2025 Management View CEO Tim Danker highlighted strong performance in the Medicare Advantage segment during the annual enrollment period, attributing success to their high-touch agent-led business model and targeted marketing efforts. He noted a 22% decrease in marketing expenses per policy year-over-year and a..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: SelectQuote (NYSE:[SLQT](https://seekingalpha.com/symbol/SLQT "SelectQuote, Inc.")) Q2 2025

### Management View

* CEO Tim Danker highlighted strong performance in the Medicare Advantage segment during the annual enrollment period, attributing success to their high-touch agent-led business model and targeted marketing efforts. He noted a 22% decrease in marketing expenses per policy year-over-year and a 24% improvement in agent close rates. The senior division achieved Adjusted EBITDA margins of 39%.
* The Healthcare Services segment, led by SelectRx, showed significant growth and profitability. Membership increased by 54% year-over-year to 97,000, contributing to consolidated revenue growth of 19% and Adjusted EBITDA growth of 30%. Danker emphasized the importance of increasing balance sheet flexibility to support future growth.
* CFO Ryan Clement reported consolidated revenue of $481 million for the quarter, with $256 million generated by the senior segment. Adjusted EBITDA for the senior division reached $101 million, reflecting a margin of 39%. He also detailed a $350 million preferred equity offering aimed at improving capital structure and reducing annual cash interest obligations by $30 million.

### Outlook

* FY2025 revenue guidance was raised to a range of $1.5 billion to $1.575 billion, up from the previous range of $1.425 billion to $1.525 billion, driven by strong Medicare Advantage and SelectRx results.
* Adjusted EBITDA guidance was increased to $115 million to $140 million, compared to the prior range of $100 million to $130 million, supported by high margins in the senior division.
* Net income guidance improved to a range of a loss of $24 million to income of $11 million, versus the prior range of a loss of $59 million to income of $3 million.

### Financial Results

* Consolidated revenue grew 19% year-over-year to $481 million, driven by the senior and healthcare services segments. Senior division revenue totaled $256 million, and SelectRx membership supported healthcare services revenue of $183 million, which grew 64% year-over-year.
* Adjusted EBITDA for the quarter was $88 million, reflecting a consolidated margin of 18%. The senior segment achieved a near-record Adjusted EBITDA margin of 39%, while healthcare services contributed $2 million of Adjusted EBITDA despite upfront investments.
* Lifetime value for Medicare Advantage policies decreased by 3% year-over-year to $907, primarily due to carrier mix rather than persistency issues.

### Q&A

* Benjamin Hendrix, RBC Capital Markets, asked about guidance and investments for the fiscal year-end. Danker stated they were pleased with the results and highlighted ongoing investments in facilities and efficiency improvements. CFO Clement mentioned margins for the senior division are expected to remain in the low to mid-20% range for the fiscal year.
* Hendrix also inquired about SelectRx growth and synergies with the senior segment. Danker noted strong attachment rates and market penetration, emphasizing the vast market opportunity beyond their existing customer base. He highlighted the potential for SelectRx to drive adherence and reduce waste.
* George Sutton, Craig-Hallum, asked about the $350 million equity offering's impact on operational flexibility. Clement explained that $260 million would be used to retire term debt, reducing interest obligations by $30 million annually, with $100 million available for operational flexibility.
* Sutton also raised concerns about agent count constraints and potential regulatory shifts. Management expressed confidence in their tenured agents' performance and noted a favorable regulatory environment for Medicare Advantage under the current administration.

### Sentiment Analysis

* Analysts maintained a positive tone, focusing on the company's growth in Medicare Advantage and SelectRx, as well as improvements in capital structure. Questions reflected interest in operational flexibility and long-term synergies.
* Management exhibited confidence in prepared remarks, emphasizing strong results and strategic investments. Danker reiterated their commitment to responsible growth and improving the balance sheet.
* Compared to the previous quarter, analysts displayed increased optimism due to improved guidance and strong performance metrics.

### Quarter-over-Quarter Comparison

* Guidance for FY2025 revenue, Adjusted EBITDA, and net income was raised from the previous quarter, reflecting stronger-than-expected performance during the Medicare Advantage annual enrollment period.
* Medicare Advantage policy volume grew 6% year-over-year, exceeding prior expectations of a 10%-15% decline.
* SelectRx membership grew 54% year-over-year compared to 64% growth in Q1, with the company noting a higher conversion rate of enrollees during the quarter.
* Management's tone remained confident, with a focus on leveraging operational efficiency and capital flexibility for future growth.

### Risks and Concerns

* Management acknowledged challenges in optimizing their capital structure, despite progress with the $350 million equity offering. They plan to pursue additional securitizations and other strategic actions.
* Analysts raised questions about agent force constraints and the potential impact of regulatory changes, though management emphasized their agent-led model's adaptability and a favorable regulatory environment.

### Final Takeaway

SelectQuote reported strong Q2 2025 results, driven by robust performance in the Medicare Advantage and SelectRx segments. The company raised FY2025 revenue and Adjusted EBITDA guidance, reflecting confidence in continued growth and operational efficiency. Strategic capital structure improvements, including a $350 million equity offering, position the company for long-term success in a favorable regulatory and market environment.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/SLQT/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4406365-selectquote-raises-fy2025-revenue-guidance-to-1_5b-1_575b-amid-strong-medicare-advantage)
